Home » Articles » News

Thailand to cease Sinovac vaccine use when stocks end this month | Inquirer News...

Thailand to cease Sinovac vaccine use when stocks end this month | Inquirer News
"A health worker holds a syringe and a vial of the Sinovac coronavirus disease (COVID-19) vaccine at a market in Bangkok, Thailand, March 17, 2021. REUTERS FILE PHOTO
BANGKOK — Thailand will stop using the COVID-19 vaccine of China’s Sinovac when its current stock finishes, a senior official said on Monday, having used the shot extensively in combination with Western-developed vaccines.
Thailand used over 31.5 million Sinovac doses since February, starting with two doses to frontline workers, high-risk groups and residents of Phuket, a holiday island that reopened to tourists early in a pilot scheme.
ADVERTISEMENT

In July, Thailand started inoculating people with Sinovac as a first dose followed by the Oxford University-developed AstraZeneca. Thailand was the first country to combine a Chinese and Western shots, a strategy its health officials said has proved effective.
“We expect to have distributed all Sinovac doses this week,” said health official Opas Karnkawinpong, adding the program will switch to combining the AstraZeneca vaccine with that made by Pfizer and BioNTech .FEATURED STORIES
NEWSINFO
Roque bares Sara Duterte’s last-minute appeal for him to run for Senate

NEWSINFO
‘Saving’ Manila Bay: Dolomite beach, wetlands drowning in wastes

NEWSINFO
Bongbong, family attend China embassy’s photo wall ribbon-cutting event

Thailand next year plans to buy 120 million COVID-19 vaccine doses in total and has already booked 60 million doses of AstraZeneca, a vaccine it manufactures locally.
Thailand has said it will only procure vaccines effective against new variants.

Recommended videosPowered by AnyClip1/7North Korea says US overreacting over missile testRead More



11.1K



2





Video Player is loading.Play VideoUnmuteDuration /Current Time Playback Speed Settings1xLoaded: 0%Remaining Time - FullscreenPlayUp NextThis is a modal window.Beginning of dialog window. Escape will cancel and close the window.TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaqueFont Size50%75%100%125%150%175%200%300%400%Text Edge StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall CapsReset restore all settings to the default valuesDoneClose Modal DialogEnd of dialog window.Playback Speed0.25x0.5x1x Normal1.5x2xReplay the listPowered by AnyClip Privacy Policy

TOP ARTICLES







































North Korea says US overreacting over missile test
NOW PLAYING
UP NEXT





Ethiopia hits Tigray's capital with third airstrike
NOW PLAYING
UP NEXT





Isko Moreno promises to cut tax on fuel, electricity by 50%
NOW PLAYING
UP NEXT





WATCH: OCEAN PARK SA MANILA, BUKAS NA | CHONA YU
NOW PLAYING
UP NEXT





WATCH: MGA MAGSASAKA, UMAARAY NA SA SMUGGLING NG GULAY NA GALING CHINA | CHONA YU
NOW PLAYING
UP NEXT





WATCH: MGA MAGSASAKA, SUMUGOD SA MENDIOLA | CHONA YU
NOW PLAYING
UP NEXT





Atienza: Makabayan endorses Pacquiao
NOW PLAYING
UP NEXT



North Korea says US overreacting over missile test





It has so far vaccinated 36% of the estimated 72 million people who live in Thailand and hopes to reach 70% by year-end.
The country is forging ahead with a quarantine-free reopening plan next month of 17 provinces to vaccinated arrivals from low risk countries. Included will be destinations like Pattaya, Hua Hin, Chiang Mai and Bangkok.
Thailand has recorded nearly 1.8 million cases and 18,336 fatalities overall, more than 98% in the past seven months.
.inline_ffff input { width: 70%!important; }
.bypro {
float: right;
width: 71%;
text-align: center;
margin-top: -12px;
margin-right: 15px;
clear: both;
color: #5C5C5C;
font-size: 8px!important;
line-height: 9px!important;

}
.lfform-inquirer-horizontal h2 {
font-weight: bold !important;
font-family: mallory !important;
}
@media only screen and (min-width: 360px) and (max-width: 767px) {
.lfform-inquirer-horizontal #myForm3 {
width: 100%;
display: flex;
flex-wrap: wrap;
justify-content: center;
}
.lfform-inquirer img {
width: 100% !important;
margin: 0 !important;
}
.bypro {
margin-top: 10px;
}
.lfform-inquirer-horizontal input[type=""email""] {

width: 100% !important;
}
.lfform-inquirer-horizontal input[type=""submit""], .lfform-inquirer-horizontal input[type=""button""] {

width: 100% !important;
}
}

.formv4 {
width: 100%!important;
max-width: 100%;
margin: 15px 0;
}
.formv4 input[type=""email""] {
font-weight: bold;
float: left;
-webkit-appearance: none;
margin: 0!important;
width: 70% !important;
}
.formv4 input[type=""submit""] {
font-weight: bold;
width: 28% !important;
padding: 3%;
float: left;
-webkit-appearance: none;
}
.formv4 #myForm3 {
width: 100%;
display: flex;
flex-wrap: wrap;
justify-content: space-between;
}
.formv4 .bypro {
width:100%;
font-family: 'noto serif';
float: unset;
clear: both;
color: #333333;
font-size: 11px!important;

line-height: 1 !important;
margin: 10px 3px;
text-align:left;
}
.formv4 a, .formv4 a:visited, .formv4 a:hover {
color: #0b72b5 !important;
text-decoration: none; !important;
}

.formv4 h2 {
font-weight: bold !important;
text-align: left;
font-family: mallory !important;
color: #333333 !important;
margin:5px 0 !important;
padding: 0 !important;
}
.formv4 p {
width: 100%;
text-align: left;
color: #5A5A5A !important;
font-family: 'noto serif' !important;
font-size: 14px !important;
margin: 0 !important;
line-height: 1.6em !important;
margin-bottom: 15px !important;
padding: 0 !important;
}

@media only screen and (min-width: 360px) and (max-width: 767px) {
.formv4 h2 {

font-size: 16px !important;
}
.formv4 .bypro {
font-size: 12px!important;
margin: 5px 5px;
}
.formv4 input[type=""email""] {

width: 100% !important;
}
.formv4 input[type=""submit""] {
width: 100% !important;
margin: 10px 0;
}
.formv4 {
width: 95%!important;
max-width: 95%;
margin: 20px auto;
}
}

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.

#inqplus-article2 {
width: 100%;
height: 250px;
margin: 20px auto;
background-color: #a5b8c5;
display: flex;
flex-wrap: wrap;
justify-content: space-between;
align-items: flex-start;
}
#inqplus-cta-wrap {
width: 50%;
height: 250px;
background-image: url(/single2017/images/inqplus-sub/inqplus-cta-bg1.png);
background-repeat: no-repeat;
background-size: cover;
}
#inqplus-cta2 {
width: 89%;
height: auto;
margin: 35px auto 0;
}
#inqplus-cta2 img {
width: 100%;
}
#newsletter-cta-wrap {
width: 50%;
height: 250px;
background-image: url(/single2017/images/inqplus-sub/newsletter-bg1.png);
position: relative;
background-repeat: no-repeat;
background-size: cover;
}
#newsletter-cta2 {
width: 95%;
position: absolute;
bottom: -4px;
z-index: 1;
}
#newsletter-cta2 img {
width: 100%;
}
#inqplus-nl-sub2 {
width: 65%!important;
display: flex;
font-size: 0;
box-sizing: border-box;
z-index: 2;
position: absolute;
bottom: 10px;
right: 10px;
}
#inqplus-nl-sub2 form {
width: 100%!important;
}
.sub-input2 {
width: 70%!important;
height: 25px!important;
border: 0!important;
padding: 5px 0 5px 10px!important;
margin: 0!important;
box-sizing: border-box!important;
border-radius:0;
-webkit-appearance:none;
}
.sub-btn2 {
width: 30%!important;
height: 25px!important;
border: 0!important;
padding: 0!important;
margin: 0!important;
background-color: #004a87!important;
color: #f5f5f5!important;
text-transform: uppercase!important;
border-radius:0;
-webkit-appearance:none;
}
/* 414px */
@media only screen and (min-width: 414px) and (max-width: 599px){
#inqplus-article2 {
width: 98%;
height: auto;
}

#inqplus-cta-wrap {
width: 100%;
height: auto;
}

#newsletter-cta-wrap {
width: 100%;
}

#newsletter-cta2 img {
width: 90%;
}

}

/* 320px */
@media only screen and (min-width: 320px) and (max-width: 413px){
#inqplus-article2 {
width: 98%;
height: auto;
}

#inqplus-cta-wrap {
width: 100%;
}

#newsletter-cta-wrap {
width: 100%;
}

}

Read Next

4 Chinese killed in PDEA-led buy-bust in Pampanga; P262-M shabu seized

VerrulonRemove Warts & Skin Tags Safely At Home! Try Out Now!Verrulon|SponsoredSponsoredUndoStudent SeaKate Middleton's Daring Outfit Took Prince William's Breath AwayStudent Sea|SponsoredSponsoredUndoDatemyage.comWhy women find older men so attractiveDatemyage.com|SponsoredSponsoredUndoBETER - leading providerSports betting odds, api for sportsbooksBETER - leading provider|SponsoredSponsoredUndoTips and Tricks[Gallery] Teenage pole vaulter's life is almost ruined after pictures go viralTips and Tricks|SponsoredSponsoredUndoDatemyage.comPhilippines Singles Age 40+ Are Finding Love With This Dating Site!Visit and check out 100% verified profiles nearbyDatemyage.com|SponsoredSponsoredUndoPerfect-Dating.comAgusan Del Norte is actually full of single handsome guys. Check them out on this free dating sitePerfect-Dating.com|SponsoredSponsoredUndo

window._taboola = window._taboola || [];
_taboola.push({
mode: 'thumbnails-d',
container: 'taboola-below-article-thumbnails-desktop',
placement: 'Below Article Thumbnails - newsinfo',
target_type: 'mix'
});


window._taboola = window._taboola || [];
_taboola.push({
mode: 'thumbnails-e',
container: 'taboola-below-article-thumbnails-mobile',
placement: 'Below Article Thumbnails - newsinfo',
target_type: 'mix'
});

EDITORS' PICK

Leaked: A 60x Zoom and all-new Helio G96 mean a complete overhaul for TECNO Mobile’s new CAMON 18 series

Pagasa: Fair weather on Thursday; cooler days coming

Delivering delight against all odds

US FDA clears Moderna, J&J COVID-19 boosters, backs use of different vaccine for boost

Next level mobile photography within reach with vivo X70 co-engineered with ZEISS

DOJ drug war review: Killer cops had it easy

MOST READ

Drilon: Tax and then ban Chinese firm in pandemic funds mess

‘Saving’ Manila Bay: Dolomite beach, wetlands drowning in wastes

Robredo to supporters: Be calm, gentle and do good deeds

DOTr signs deal with Chinese firm for Phase 1 of Mindanao Railway project

Don't miss out on the latest news and information.

View comments"
 

Please support us in writing articles like this by sharing this post

Share this post to your Facebook, Twitter, Blog, or any social media site. In this way, we will be motivated to write articles you like.

--- NOTICE ---
If you want to use this article or any of the content of this website, please credit our website (www.affordablecebu.com) and mention the source link (URL) of the content, images, videos or other media of our website.

"Thailand to cease Sinovac vaccine use when stocks end this month | Inquirer News" was written by Mary under the News category. It has been read 57 times and generated 0 comments. The article was created on and updated on 17 November 2021.
Total comments : 0